来自囊性纤维化肺部的上皮干细胞变体的炎症活性未被CFTR调节器解决
Shan Wang1, Suchan Niroula1, Ashley Hoffman1
1Department of Biology and Biochemistry, University of Houston, Houston, Texas.
American journal of respiratory and critical care medicine
|September 11, 2023
概括
囊性纤维化 (CF) 肺部有助于炎症的干细胞变体,尽管CFTR调节器治疗仍存在. 这些变体有助于在晚期CF疾病中持续的肺炎.
科学领域:
- 肺部医学 肺部医学
- 干细胞生物学 干细胞生物学
- 遗传学 遗传学 是一个
背景情况:
- 囊性纤维化跨膜导电调节器 (CFTR) 调节器可以改善肺功能,但不能完全消除炎症.
- 囊性纤维化 (CF) 患者的持续性肺炎需要确定新的治疗点.
- 了解CF肺部的干细胞异质性对于管理晚期疾病至关重要.
研究的目的:
- 研究CF肺部的干细胞变体及其对炎症的贡献.
- 为了识别特定的干细胞变异驱动中性友好性炎症在CF.
- 评估CFTR基因补充和调制剂对这些变异的影响.
主要方法:
- 应用干细胞克隆和单细胞RNA测序到末期CF肺部.
- 在免疫缺陷小鼠中通过RNA测序和异种移植评估干细胞克隆.
- 评估了CFTR活动恢复对已识别的变体的影响.
主要成果:
- 在CF肺部识别了除了正常干细胞之外的五种主要干细胞变异.
- 三种变体表现出促炎症的基因表达,并在异种移植中诱导了中性恋炎症.
- 这些变体的抗炎功能不受CFTR遗传或药理修复的影响.
结论:
- 亲炎性干细胞变体在CF肺部出现,导致持续的炎症.
- 这些变体可能是晚期囊性纤维化治疗的治疗点.
- 目前的CFTR调节器疗法不能完全解决由这些干细胞变异驱动的炎症.
相关概念视频
Cystic Fibrosis: Management
191
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
191
Cystic Fibrosis: Pathogenesis
275
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
275
Renewal of Intestinal Stem Cells
2.6K
The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.6K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
Antiasthma Drugs: Leukotriene Modifiers
343
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
343


